Patent-protected Motif interface proven in independent studies as equivalent method to capture patient reported outcome and eDiary data; eliminates reliance on text-based instruments for clinical trials, real-world studies
BOSTON, Feb. 14, 2023 /PRNewswire-PRWeb/ -- uMotif, one of the clinical trial technology market's fastest growing companies, was awarded Best of Show for its groundbreaking Motif data capture interface by attendees of the SCOPE Summit for Clinical Ops Executives in Orlando last week.
The Motif is a patented, flower-like graphical user interface. Each petal represents a different question, such as an Outcome Measure, symptom, or eDiary entry. Patients swipe on each petal to capture their data. The highly visual and easy-to-use interface is fast and engaging, which leads to higher rates of data capture compliance. The Motif was independently validated by SAFIRA Clinical Research as the first new alternative to text-based instruments for clinical, post-marketing and real-world research since paper instruments were deployed on smartphones. (Read more about the study here)
uMotif's highly scalable eCOA/ePRO platform combines deep clinical knowledge and consumer design expertise to deliver unprecedented levels of patient compliance, regularly achieving greater than 90% data capture in real-world studies. uMotif meets clinical and RWE market needs in any country, language, therapeutic area, and participant population, supporting site-based, hybrid, and fully virtual decentralized trials. Available on iOS, Android and the Web, the uMotif platform supports the most widely-used eCOA/ePRO and eDiary input and evaluation types.
uMotif CEO Steve Rosenberg (LinkedIn) said, "it's a huge honor to be recognized by your peers, and we're grateful. The Motif was born from our guiding principle that clinical research patients are heroes, and we give them technology that keeps them motivated, active and compliant. When patients stay engaged, sponsors and CROs capture more and better-quality data, so they can speed the delivery of new medicines to people who are waiting."
About uMotif
Putting patients first is in uMotif's DNA. The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to decentralized or virtual real-world studies. Find out how uMotif can improve your clinical research programs and real-world studies at http://www.umotif.com
Media Contact
Brenda Nashawaty, uMotif, 1 6176883253, [email protected]
Elaine Maynard, uMotif, 6176883253, [email protected]
SOURCE uMotif
Share this article